Desferrioxamine ototoxicity in an adult transfusion-dependent population

Journal of Otolaryngology

Volumn 26, Issue 2, 1997, Pages 116-122

  Chiodo, Al A ^a   Alberti, Peter W ^a   Sher, Graham D ^a   Francombe, William H ^a   Tyler, Bev ^a  

^a NONE

Author keywords

desferrioxamine; L1; ototoxicity; thalassemia

Indexed keywords

DEFEROXAMINE; DEFEROXAMINE MESYLATE; IRON;

ADULT; AGED; ARTICLE; BLACKFAN DIAMOND ANEMIA; BLOOD TRANSFUSION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; IRON BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OTOTOXICITY; PRIORITY JOURNAL; SICKLE CELL ANEMIA; SUBCUTANEOUS DRUG ADMINISTRATION; THALASSEMIA MAJOR;

ADULT; AGED; ANEMIA, SICKLE CELL; AUDIOMETRY; BETA-THALASSEMIA; BLOOD TRANSFUSION; DEFEROXAMINE; DRUG MONITORING; FANCONI ANEMIA; FEMALE; HEARING DISORDERS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; SIDEROPHORES;

EID: 0030975897     PISSN: 03816605     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Boelaert JR, de Locht M. Side-effects of desferrioxamine in dialysis patients. Nephrol Dial Transplant 1993; 8(suppl 1): 43-46.
2. Olivieri NF, Buncic JR, Chew E, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferrioxamine infusions. N Engl J Med 1986; 314:869-873.
3. Cohen A, Martin M, Mizanin J, et al. Vision and hearing during deferrioxamine therapy. J Pediatr 1990; 117:326-330.
4. Orton RB, de Veber LL, Sulh HMB. Ocular and auditory toxicity of long-term, high dose subcutaneous deferoxamine therapy. Can J Ophthalmol 1985; 20:153.
5. Albera R, Pia F, Morra B. Hearing loss and deferrioxamine in homozygous beta thalassemia. Audiology 1988; 27:207-214.
6. Argiolu F, Diana G, Avignone A, et al. Hearing impairment during deferoxamine therapy for thalassemia major. J Pediatr 1991; 118:826-827.
7. De Virgiliis S, Argiolu F, Sanna G et al. Auditory involvement in thalassemia major. Acta Haematol 1979; 61:209-215.
8. Gallant T, Boyden MH, Gallant LA et al. Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy. Am J Med 1987; 83:1085-1090.
9. Guerin A, London G, Marchais S, et al. Acute deafness and deferoxamine. Lancet 1985; 11:39-40.
10. Masala W, Meloni F, Gallisai D, et al. Can deferoxamine be considered an ototoxic drug? Scand Audiol Suppl 1988; 30: 237-238.
11. Porter JB, Jaswon MS, Huehns ER, et al. Desferrioxamine ototoxicity: evaluation of risk factors in thalassemic patients and guidelines for safe dosage. Br J Haematol 1989; 73: 403-409.
12. Chiodo AA, Alberti PW. Experimental, clinical and preventive aspects of ototoxicity. Eur Arch Otorhinolaryngol 1994; 251:375-392.
13. Kontzoglou G, Koussi A, Tsatri J, et al. Sensorineural hearing loss in children with thalassemia major in Northern Greece. Int J Pediatr Otorhinolaryngol 1996; 35:223-230.
14. Mosciaro D, Borgatti L. La funzione uditiva nel morbo di Cooley. In: Atti Gioranate di Studio Microcitemia. Vol. 1. Ferrara: 1986:184-186.
15. Hazell JWP, Modell CB. ENT complications in thalassemia major. J Laryngol Otol 1976; 90:877-881.
16. Logothetis J, Constantoulakis M, Economidou J, et al. Thalassemia major: a survey of 138 cases with emphasis on neurologic and muscular aspects. Neurology 1972; 22:294-304.
17. Henderson D, McFadden SL, Gratton MA, Spongr VP. Similarities and differences between noise induced and age related hearing loss. In: Rossi G, ed. Proceedings of the International Advanced Research Workgroup. Turin: Audiological Meetings, 1995:69-92.
18. Brummett RE, Morrison RB. The incidence of aminoglycoside antibiotic-induced hearing loss. Arch Otolaryngol Head Neck Surg 1990; 116:406-410.
19. Wonke B, Hoffbrand AV, Aldouri M, et al. Reversal of desferrioxamine induced auditory neurotoxicity during treatment with Ca-DTPA. Arch Dis Child 1989; 64:77-82.
20. Shirane M, Harrison RV. The effects of deferoxamine mesylate and hypoxia on the cochlea. Acta Otolaryngol 1987; 104:99-107.
21. Kanno H, Yamanobe S, Rybak LP. The ototoxicity of desferoxamine mesylate. Am J Otolaryngol 1995; 148-152.